Changes

Jump to: navigation, search

Combining-Olanzapine-Valproic acid

990 bytes added, 20:31, 9 March 2010
Created page with '{{Drugcombi | base = olanzapine | add = valproic acid | info = * Olanzapine is principally metabolized by CYP1A2 and CYP2D6. * Valproic acid is principally metabolized by CYP2C9...'
{{Drugcombi
| base = olanzapine
| add = valproic acid
| info =
* Olanzapine is principally metabolized by CYP1A2 and CYP2D6.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination.
| start =
* Start valproic acid according to the general dosing advice. Monitoring of the liver function every 3 to 4 months during the first year of treatment with either olanzapine or valproic acid is recommended.<ref name="drugscom">
{{Drugscominteract|olanzapine-with-valproic-acid-1744-0-2286-0|olanzapine|valproic acid}}</ref>
| cave =
* Concurrent use of olanzapine and valproic acid may potentiate the risk of hepatotoxicity.<ref name="drugscom" />
}}
387
edits

Navigation menu